Limber

About Limber

Limber Health operates as a digital health company focused on the musculoskeletal (MSK) market by providing a hybrid care model that combines in-person and digital solutions. The company was founded in 2019 by brothers Dr. Marc Gruner, a sports medicine physician, and Michael Gruner, who serves as CEO. Marc Gruner's experience working on orthopedic payment models at the Center for Medicare and Medicaid Innovation highlighted the need for a better home exercise and care management platform to address low patient adherence to physical therapy. Michael Gruner brought experience from business consulting at Accenture and as a former founder.

Limber Health partners with physical and occupational therapists, healthcare providers, payers, and employers to augment in-clinic care with a suite of digital tools. The business model is centered on empowering existing providers rather than replacing them, offering a B2B platform that integrates with their workflows. Revenue is generated through this partnership model, which includes providing tools for the new Remote Therapeutic Monitoring (RTM) CPT codes that the company helped establish with the American Medical Association (AMA), enabling clinicians to receive reimbursement for monitoring patients remotely.

The company's platform provides a digital toolkit that includes at-home video exercise programs, patient-reported outcomes collection, remote therapeutic monitoring (RTM), MIPS reporting, and data analytics. A key feature is its risk stratification tool, which assesses patients and assigns tailored exercise programs. The platform is designed to increase patient engagement and adherence to treatment plans, which can lead to better outcomes and reduced healthcare costs by avoiding more expensive interventions like surgery. The clinical effectiveness of Limber's approach has been validated in two clinical studies at the Mayo Clinic, with one randomized controlled trial finding the app superior to conventional in-person physical therapy for reducing pain and improving function in patients with knee pain. The company secured an $11 million Series A funding round in October 2022, led by Blue Venture Fund and Glenview Capital, to expand its platform and partnerships.